Wesana CEO talks mental health, psychedelics, challenges and more
In this edition of “Rising High,” The Fly conducted an exclusive interview with Daniel Carcillo, founder and chief executive officer of Wesana Health (WSNAF), a data-driven life science company focused on developing the novel therapies of tomorrow and delivering new care paradigms today. Here are some highlights:
TRANSCENDING BARRIERS: Wesana Health’s drug development program looks to utilize combination therapy to address migraine and symptoms of Traumatic Brain Injury, like depression and anxiety. Using psilocybin and cannabidiol, Wesana’s lead drug candidate SANA-013 targets the improvement of neuroplasticity while acting as an anti-neuroinflammatory.
“Wesana was born out of a need for traumatic brain injury survivors after I recovered my brain health and quality of life using high and low dose forms of psilocybin over a two and a half year/three-year period,” Carcillo said. “There is no approved pharmaceutical treatment for traumatic brain injury, which has an incidence rate over 5.6M new cases a year. TBI is severely underreported and over half of those cases deal with long-term, lifetime issues.”
To see the rest of the story Click Here.